| Year |
Citation |
Score |
| 2020 |
Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, Barr PM, Winegarden JD, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, LeBlanc ML, Song JY, Fisher RI, et al. Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2000999. PMID 32658627 DOI: 10.1200/Jco.20.00999 |
0.388 |
|
| 2020 |
Ha CS, LeBlanc M, Schöder H, Pinnix CC, Bartlett NL, Evens AM, Hsi ED, Rimsza L, Knopp MV, Zhang J, Leonard JP, Kahl BS, Li H, Smith S, Constine LS, et al. Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. Leukemia & Lymphoma. 1-6. PMID 32452714 DOI: 10.1080/10428194.2020.1768388 |
0.349 |
|
| 2019 |
Dai JY, LeBlanc M. Case-only trees and random forests for exploring genotype-specific treatment effects in randomized clinical trials with dichotomous endpoints. Journal of the Royal Statistical Society. Series C, Applied Statistics. 68: 1371-1391. PMID 32489221 DOI: 10.1111/Rssc.12366 |
0.326 |
|
| 2019 |
Kamdar M, Li H, Chen RW, Rimsza LM, Leblanc ML, Fenske TS, Shea TC, Barr PM, Phillips TJ, Leonard JP, Kahl BS, Friedberg JW, Smith SM. Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. Blood Advances. 3: 3132-3135. PMID 31648328 DOI: 10.1182/Bloodadvances.2019000526 |
0.388 |
|
| 2019 |
Zhao YQ, LeBlanc ML. Designing precision medicine trials to yield greater population impact. Biometrics. PMID 31598964 DOI: 10.1111/Biom.13161 |
0.364 |
|
| 2019 |
Zhao YQ, Redman MW, LeBlanc ML. Quantifying treatment effects using the personalized chance of longer survival. Statistics in Medicine. PMID 31502297 DOI: 10.1002/Sim.8363 |
0.375 |
|
| 2019 |
Zhao YQ, Zeng D, Tangen CM, LeBlanc ML. Robustifying Trial-Derived Optimal Treatment Rules for A Target Population. Electronic Journal of Statistics. 13: 1717-1743. PMID 31440323 DOI: 10.1214/19-Ejs1540 |
0.323 |
|
| 2019 |
Unger JM, Blanke CD, LeBlanc ML, Barlow WE, Hershman DL. Patients enrolled in clinical trials with Medicaid or no insurance and overall survival benefits from new interventions. Journal of Clinical Oncology. 37: 119-119. DOI: 10.1200/Jco.2019.37.27_Suppl.119 |
0.398 |
|
| 2019 |
Unger JM, Nghiem VT, Hershman DL, Vaidya R, LeBlanc ML, Blanke CD. The impact of NCI-sponsored network group clinical trials on guideline care and new drug indications. Journal of Clinical Oncology. 37: 6604-6604. DOI: 10.1200/Jco.2019.37.15_Suppl.6604 |
0.314 |
|
| 2019 |
Unger JM, Vaidya R, Albain KS, LeBlanc ML, Minasian LM, Gotay C, Henry NL, Fisch MJ, Ramsey SD, Blanke CD, Lyman GH, Hershman DL. Sex differences in adverse event reporting in SWOG chemotherapy, biologic/immunotherapy, and targeted agent cancer clinical trials. Journal of Clinical Oncology. 37: 11588-11588. DOI: 10.1200/Jco.2019.37.15_Suppl.11588 |
0.302 |
|
| 2019 |
Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, Barr PM, Winegarden JD, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, Leblanc ML, Song JY, Fisher RI, et al. PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001 Blood. 134: 349-349. DOI: 10.1182/Blood-2019-123871 |
0.318 |
|
| 2019 |
Burack R, Li H, Adlowitz DG, Spence JM, Leblanc ML, Rimsza LM, Braziel RM, Spier CM, Kaminski MS, Leonard JP, Fisher RI, Smith SM, Friedberg JW. Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of SWOG S0016 Blood. 134: 2771-2771. DOI: 10.1182/Blood-2019-121632 |
0.341 |
|
| 2018 |
Unger JM, Barlow WE, Tangen CM, Ramsey SD, Thompson IM, Klein EA, LeBlanc M, Blanke CD, Goodman PJ, Minasian LM, Nghiem VT, Hershman DL. The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials. Cancer Epidemiology. 55: 117-122. PMID 29936140 DOI: 10.1016/J.Canep.2018.06.005 |
0.339 |
|
| 2018 |
Rimsza LM, Li H, Braziel RM, Spier CM, Persky DO, Dunlap J, LeBlanc M, Bartlett N, Leonard JP, Smith SM, Press OW, Friedberg JW. Impact of histologic grading on survival in the SWOG S0016 follicular lymphoma cohort. Haematologica. PMID 29472351 DOI: 10.3324/Haematol.2017.175059 |
0.342 |
|
| 2018 |
Ha CS, Li H, Schoder H, Pinnix CC, Brem E, Bartlett NL, Evens AM, Hsi ED, Rimsza LM, Leonard JP, Kahl BS, Leblanc ML, Smith SM, Constine LS, Friedberg JW. Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis Blood. 132: 2927-2927. DOI: 10.1182/Blood-2018-99-113133 |
0.337 |
|
| 2018 |
Stephens DM, Li H, Schoder H, Straus DJ, Moskowitz CH, Leblanc ML, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr P, Knopp MV, Hsi ED, Leonard JP, Kahl BS, et al. Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach Blood. 132: 929-929. DOI: 10.1182/Blood-2018-99-113034 |
0.373 |
|
| 2018 |
Kamdar M, Li H, Chen RW, Rimsza LM, Leblanc ML, Fenske TS, Barr P, Phillips TJ, Leonard JP, Kahl BS, Friedberg JW, Smith SM. Five-Year Outcomes of SWOG S1106: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Mantle Cell Lymphoma Blood. 132: 1593-1593. DOI: 10.1182/Blood-2018-99-112752 |
0.392 |
|
| 2018 |
Burack R, Li H, Spence JM, Adlowitz D, Rimsza LM, Braziel RM, Spier CM, Kaminski MS, Leonard JP, Fisher RI, Leblanc ML, Smith SM, Friedberg JW. Subclonal Mutations of TP53 Are Common in Untreated Follicular Lymphoma and Mutation Status Is Predictive of PFS When CHOP Is Combined with 131-Iodine Tositumomab but Not with Rituximab: An Analysis of SWOG S0016 Blood. 132: 919-919. DOI: 10.1182/Blood-2018-99-111399 |
0.318 |
|
| 2017 |
Smith EP, Li H, Friedberg JW, Constine LS, Rimsza LM, Cook JR, Laport GG, Popplewell LL, Holmberg LA, Smith SM, LeBlanc M, Forman SJ, Fisher RI, Stiff PJ. Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: a SWOG and Blood & Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29289757 DOI: 10.1016/J.Bbmt.2017.12.798 |
0.398 |
|
| 2017 |
Dai JY, Liang CJ, LeBlanc M, Prentice RL, Janes H. Case-only approach to identifying markers predicting treatment effects on the relative risk scale. Biometrics. PMID 28960244 DOI: 10.1111/Biom.12789 |
0.324 |
|
| 2017 |
Unger JM, LeBlanc M, Blanke CD. The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population. Jama Oncology. PMID 28586789 DOI: 10.1001/Jamaoncol.2017.0762 |
0.317 |
|
| 2017 |
Spurgeon SE, Till BG, Martin P, Goy AH, Dreyling MP, Gopal AK, LeBlanc M, Leonard JP, Friedberg JW, Baizer L, Little RF, Kahl BS, Smith MR. Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. Journal of the National Cancer Institute. 109. PMID 28040733 DOI: 10.1093/Jnci/Djw263 |
0.406 |
|
| 2017 |
Unger JM, LeBlanc ML, Blanke CD. The impact of positive SWOG treatment trials on population survival. Journal of Clinical Oncology. 35: 6513-6513. DOI: 10.1200/Jco.2017.35.15_Suppl.6513 |
0.328 |
|
| 2017 |
Unger JM, Barlow WE, Tangen CM, Ramsey SD, Thompson IM, Klein EA, LeBlanc ML, Blanke CD, Goodman PJ, Minasian LM, Hershman DL. The scientific impact and value of large, NCI-sponsored randomized phase III cancer prevention trials. Journal of Clinical Oncology. 35: 1541-1541. DOI: 10.1200/Jco.2017.35.15_Suppl.1541 |
0.357 |
|
| 2017 |
Stephens DM, Li H, Persky D, Park SI, Bartlett NL, Swinnen LJ, Casulo C, Winegarden JD, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, Leblanc ML, Song JY, Fisher RI, et al. Characteristics and Outcomes of Patients with Double-Protein Expression in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of SWOG Study S1001 (NCT01359592) Blood. 130: 4122-4122. DOI: 10.1182/Blood.V130.Suppl_1.4122.4122 |
0.369 |
|
| 2017 |
Hsi ED, Li H, Nixon AB, Evens AM, Schoder H, Straus DJ, Bartlett NL, Sweetenham JW, Barr PM, Fanale MA, Cook JR, Kahl BS, Leonard JP, Smith SM, Leblanc ML, et al. Prognostic Utility of Serum TARC, MDC, IL10, and Soluble CD163 Levels with Positron Emission Tomography (PET) Response-Adapted Therapy for Advanced-Stage Hodgkin Lymphoma (HL): a SWOG S0816 US Intergroup Correlative Study Blood. 130: 4033-4033. DOI: 10.1182/Blood.V130.Suppl_1.4033.4033 |
0.301 |
|
| 2017 |
Persky D, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, Barr PM, Winegarden JD, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, Leblanc ML, Song JY, Fisher RI, et al. A Phase II Intergroup Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG Study S1001 (NCT01359592) Blood. 130: 1553-1553. DOI: 10.1182/Blood.V130.Suppl_1.1553.1553 |
0.32 |
|
| 2017 |
Scott DW, Li H, Harvey Y, Chan F, Mottok A, Boyle M, Evens AM, Schoder H, Straus DJ, Bartlett NL, Sweetenham JW, Barr PM, Fanale MA, Hsi ED, Cook JR, ... ... Leblanc M, et al. The 23‐Gene Gene Expression‐Based Assay Does Not Predict Interim Pet Scan Results After Abvd In Advanced Stage Classical Hodgkin Lymphoma In The Us Intergroup S0816 Trial Hematological Oncology. 35: 92-93. DOI: 10.1002/Hon.2437_81 |
0.343 |
|
| 2016 |
Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, Fenske TS, Barr PM, Phillips T, Leblanc M, Fisher RI, et al. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. British Journal of Haematology. PMID 27992063 DOI: 10.1111/bjh.14480 |
0.303 |
|
| 2016 |
Greenlee H, Unger JM, LeBlanc M, Ramsey S, Hershman DL. Association between Body Mass Index and Cancer Survival in a Pooled Analysis of 22 Clinical Trials. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 27986655 DOI: 10.1158/1055-9965.Epi-15-1336 |
0.334 |
|
| 2016 |
Stephens DM, Li H, LeBlanc ML, Puvvada SD, Persky D, Friedberg JW, Smith SM. Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27382104 DOI: 10.1200/Jco.2015.65.4582 |
0.388 |
|
| 2016 |
Puvvada SD, Stiff PJ, Leblanc M, Cook JR, Couban S, Leonard JP, Kahl B, Marcellus D, Shea TC, Winter JN, Li H, Rimsza LM, Friedberg JW, Smith SM. Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. British Journal of Haematology. PMID 27072903 DOI: 10.1111/Bjh.14100 |
0.349 |
|
| 2016 |
Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, et al. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27069074 DOI: 10.1200/Jco.2015.63.1119 |
0.353 |
|
| 2016 |
Dazard JE, Choe M, LeBlanc M, Rao JS. Cross-validation and Peeling Strategies for Survival Bump Hunting using Recursive Peeling Methods. Statistical Analysis and Data Mining. 9: 12-42. PMID 27034730 DOI: 10.1002/Sam.11301 |
0.376 |
|
| 2016 |
Unger JM, Barlow WE, Ramsey SD, LeBlanc M, Blanke CD, Hershman DL. The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials. Jama Oncology. PMID 26967260 DOI: 10.1001/Jamaoncol.2015.6487 |
0.368 |
|
| 2016 |
LeBlanc M, Tangen C. Surrogates for Survival or Other End Points in Oncology. Jama Oncology. 2: 263-4. PMID 26605695 DOI: 10.1001/Jamaoncol.2015.4711 |
0.326 |
|
| 2015 |
Kelly JL, Salles G, Goldman B, Fisher RI, Brice P, Press O, Casasnovas O, Maloney DG, Soubeyran P, Rimsza L, Haioun C, Xerri L, LeBlanc M, Tilly H, Friedberg JW. Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1482-90. PMID 25823738 DOI: 10.1200/Jco.2014.57.5092 |
0.341 |
|
| 2015 |
Unger JM, Hershman DL, Martin D, Etzioni RB, Barlow WE, LeBlanc M, Ramsey SR. The diffusion of docetaxel in patients with metastatic prostate cancer. Journal of the National Cancer Institute. 107. PMID 25540245 DOI: 10.1093/Jnci/Dju412 |
0.368 |
|
| 2015 |
Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea BD, Press OW, Constine LS, Barton KP, Friedberg JW, LeBlanc M, Fisher RI. Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood. 125: 236-41. PMID 25395425 DOI: 10.1182/Blood-2014-06-584623 |
0.361 |
|
| 2015 |
Greenlee H, Unger J, LeBlanc M, Hershman DL. Abstract A44: Association between BMI at treatment initiation and cancer survival across multiple SWOG trials Cancer Prevention Research. 8. DOI: 10.1158/1940-6215.Prev-14-A44 |
0.363 |
|
| 2014 |
Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, Rubinstein L, Huang E, Collyar D, Groshen S, Reeves S, Ellis LM, Sargent DJ, Rosner GL, LeBlanc ML, et al. Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4210-7. PMID 25125258 DOI: 10.1158/1078-0432.Ccr-14-0521 |
0.346 |
|
| 2014 |
Philip PA, Chansky K, LeBlanc M, Rubinstein L, Seymour L, Ivy SP, Alberts SR, Catalano PJ, Crowley J. Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4176-85. PMID 24914040 DOI: 10.1158/1078-0432.Ccr-13-2024 |
0.423 |
|
| 2014 |
Gustafson HL, Yao S, Goldman BH, Lee K, Spier CM, LeBlanc ML, Rimsza LM, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Slager SL, Persky DO, Miller TP, Fisher RI, et al. Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. American Journal of Hematology. 89: 639-45. PMID 24633940 DOI: 10.1002/Ajh.23709 |
0.32 |
|
| 2014 |
Unger JM, Barlow WE, Martin DP, Ramsey SD, Leblanc M, Etzioni R, Hershman DL. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. Journal of the National Cancer Institute. 106: dju002. PMID 24627276 DOI: 10.1093/Jnci/Dju002 |
0.393 |
|
| 2014 |
Barr PM, Li H, Spier CM, Mahadevan D, Friedberg JW, LeBlanc ML, Ul Haq M, Flowers C, Wagner-Johnston ND, Cheson BD, Horwitz SM, Miller TP, Fisher RI. U.S. Intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881). Journal of Clinical Oncology. 32: 8523-8523. DOI: 10.1200/Jco.2014.32.15_Suppl.8523 |
0.318 |
|
| 2014 |
Smith EP, Li H, Friedberg JW, Constine L, Rimsza LM, Laport GG, Popplewell LL, Maloney DG, Leblanc M, Forman SJ, Fisher RI, Stiff PJ. SWOG S0410/BMT CTN 0703: A Phase II Trial of Tandem Autologous Stem Cell Transplantation (AHCT) for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma (HL) (ClinicalTrials.gov Identifier: NCT00233987) Blood. 124: 676-676. DOI: 10.1182/Blood.V124.21.676.676 |
0.374 |
|
| 2014 |
Puvvada SD, Stiff PJ, Leblanc M, Cook JR, Kahl B, Li H, Rimsza LM, Friedberg JW, Smith SM. MYC Associated and Double Protein Lymphoma: Subset Analysis of SWOG S9704 Blood. 124: 1710-1710. DOI: 10.1182/Blood.V124.21.1710.1710 |
0.343 |
|
| 2013 |
Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, ... ... LeBlanc M, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. The New England Journal of Medicine. 369: 1681-90. PMID 24171516 DOI: 10.1056/Nejmoa1301077 |
0.347 |
|
| 2013 |
Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6624-32. PMID 24130072 DOI: 10.1158/1078-0432.Ccr-13-1120 |
0.414 |
|
| 2013 |
Redman MW, Goldman BH, LeBlanc M, Schott A, Baker LH. Modeling the relationship between progression-free survival and overall survival: the phase II/III trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2646-56. PMID 23669424 DOI: 10.1158/1078-0432.Ccr-12-2939 |
0.347 |
|
| 2013 |
Bernstein SH, Epner E, Unger JM, Leblanc M, Cebula E, Burack R, Rimsza L, Miller TP, Fisher RI. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 1587-93. PMID 23504948 DOI: 10.1093/Annonc/Mdt070 |
0.352 |
|
| 2013 |
Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 314-20. PMID 23233710 DOI: 10.1200/Jco.2012.42.4101 |
0.416 |
|
| 2013 |
Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, LeBlanc M, Fisher RI, Miller TP. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer. 119: 371-9. PMID 22833464 DOI: 10.1002/Cncr.27733 |
0.369 |
|
| 2012 |
Dai JY, Kooperberg C, Leblanc M, Prentice RL. Two-stage testing procedures with independent filtering for genome-wide gene-environment interaction. Biometrika. 99: 929-944. PMID 23843674 DOI: 10.1093/Biomet/Ass044 |
0.313 |
|
| 2012 |
Othus M, Barlogie B, Leblanc ML, Crowley JJ. Cure models as a useful statistical tool for analyzing survival. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3731-6. PMID 22675175 DOI: 10.1158/1078-0432.Ccr-11-2859 |
0.344 |
|
| 2012 |
Schilsky RL, Doroshow JH, LeBlanc M, Conley BA. Development and Use of Integral Assays in Clinical Trials Clinical Cancer Research. 18: 1540-1546. PMID 22422406 DOI: 10.1158/1078-0432.Ccr-11-2202 |
0.338 |
|
| 2012 |
LeBlanc ML, Tangen CM. Choosing Phase II Endpoints and Designs: Evaluating the Possibilities Clinical Cancer Research. 18: 2130-2132. PMID 22407830 DOI: 10.1158/1078-0432.Ccr-12-0454 |
0.328 |
|
| 2012 |
Rudser KD, LeBlanc ML, Emerson SS. Distribution-free inference on contrasts of arbitrary summary measures of survival. Statistics in Medicine. 31: 1722-37. PMID 22362470 DOI: 10.1002/Sim.4505 |
0.34 |
|
| 2012 |
Press OW, Unger JM, LeBlanc ML, Rimsza LM, Friedberg JW, Czuczman MS, Kaminski MS, Braziel RM, Spier CM, Maloney DG, Cheson BD, Miller TP, Fisher RI. A phase III randomized intergroup trial (S0016) comparing CHOP plus rituximab with CHOP plus iodine-131-tositumomab for front-line treatment of follicular lymphoma: Results of subset analyses and a comparison of prognostic models. Journal of Clinical Oncology. 30: 8001-8001. DOI: 10.1200/Jco.2012.30.15_Suppl.8001 |
0.428 |
|
| 2012 |
Kelly JL, Salles G, Goldman BH, Fisher RI, Casasnovas O, Press OW, Maloney DG, Soubeyran P, Rimsza LM, LeBlanc M, Tilly H, Friedberg JW. Low Serum Vitamin D Levels Are Associated with Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and Lysa Studies. Blood. 120: 2712-2712. DOI: 10.1182/Blood.V120.21.2712.2712 |
0.356 |
|
| 2011 |
Stiff PJ, Unger JM, Cook J, Constine LS, Couban S, Shea TC, Winter JN, Miller TP, Tubbs RR, Marcellus DC, Friedberg JW, Barton K, Mills GM, LeBlanc ML, Rimsa L, et al. Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 8001. PMID 28023022 DOI: 10.1200/Jco.2011.29.15_Suppl.8001 |
0.339 |
|
| 2011 |
Rimsza LM, Unger JM, Tome ME, LeBlanc ML. A strategy for full interrogation of prognostic gene expression patterns: exploring the biology of diffuse large B cell lymphoma. Plos One. 6. PMID 21829609 DOI: 10.1371/Journal.Pone.0022267 |
0.307 |
|
| 2011 |
Rubinstein L, Leblanc M, Smith MA. More randomization in phase II trials: necessary but not sufficient. Journal of the National Cancer Institute. 103: 1075-7. PMID 21709273 DOI: 10.1093/Jnci/Djr238 |
0.387 |
|
| 2011 |
Hoering A, LeBlanc M, Crowley JJ. Seamless Phase I/II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents Clinical Cancer Research. 17: 640-646. PMID 21135145 DOI: 10.1158/1078-0432.Ccr-10-1262 |
0.321 |
|
| 2010 |
Tardif HL, Yao S, Goldman BH, Spier CM, LeBlanc ML, Rimsza LM, Persky DO, Miller TP, Fisher RI, Ambrosone CB, Briehl MM. Genetic Polymorphisms In Oxidative Stress-Related Genes Correlated with Outcome Following Anthracycline-Based Therapy for Aggressive B-Cell Non-Hodgkin Lymphomas Blood. 116: 321-321. DOI: 10.1182/Blood.V116.21.321.321 |
0.324 |
|
| 2009 |
Yoo GH, Moon J, Leblanc M, Lonardo F, Urba S, Kim H, Hanna E, Tsue T, Valentino J, Ensley J, Wolf G. A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. Archives of Otolaryngology--Head & Neck Surgery. 135: 869-74. PMID 19770418 DOI: 10.1001/Archoto.2009.122 |
0.301 |
|
| 2009 |
LeBlanc M, Rankin C, Crowley J. Multiple Histology Phase II Trials Clinical Cancer Research. 15: 4256-4262. PMID 19549777 DOI: 10.1158/1078-0432.Ccr-08-2069 |
0.364 |
|
| 2009 |
Rubinstein L, Crowley J, Ivy P, Leblanc M, Sargent D. Randomized phase II designs. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1883-90. PMID 19276275 DOI: 10.1158/1078-0432.Ccr-08-2031 |
0.35 |
|
| 2009 |
Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 114-9. PMID 19047289 DOI: 10.1200/Jco.2008.16.8021 |
0.343 |
|
| 2008 |
Rimsza LM, Leblanc ML, Unger JM, Miller TP, Grogan TM, Persky DO, Martel RR, Sabalos CM, Seligmann B, Braziel RM, Campo E, Rosenwald A, Connors JM, Sehn LH, Johnson N, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood. 112: 3425-33. PMID 18544678 DOI: 10.1182/Blood-2008-02-137372 |
0.357 |
|
| 2008 |
Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, Miller TP. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2258-63. PMID 18413640 DOI: 10.1200/Jco.2007.13.6929 |
0.363 |
|
| 2008 |
Goldman B, LeBlanc M, Crowley J. Interim futility analysis with intermediate endpoints. Clinical Trials. 5: 14-22. PMID 18283075 DOI: 10.1177/1740774507086648 |
0.414 |
|
| 2008 |
Miller TP, Unger JM, Spier C, Stea B, Press OW, Friedberg JW, LeBlanc M, Fisher RI. Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG 0313) Blood. 112: 3598-3598. DOI: 10.1182/Blood.V112.11.3598.3598 |
0.397 |
|
| 2007 |
Agrawal A, Moon J, Davis RK, Sakr WA, Giri SPG, Valentino J, LeBlanc M, Truelson JM, Yoo GH, Ensley JF, Schuller DE. Transoral carbon dioxide laser supraglottic laryngectomy and irradiation in stage I, II, and III squamous cell carcinoma of the supraglottic larynx: Report of southwest oncology group phase 2 trial S9709 Archives of Otolaryngology-Head & Neck Surgery. 133: 1044-1050. PMID 17938330 DOI: 10.1001/Archotol.133.10.1044 |
0.361 |
|
| 2007 |
Roberts RA, Sabalos CM, LeBlanc ML, Martel RR, Frutiger YM, Unger JM, Botros IW, Rounseville MP, Seligmann BE, Miller TP, Grogan TM, Rimsza LM. Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. Laboratory Investigation; a Journal of Technical Methods and Pathology. 87: 979-97. PMID 17700562 DOI: 10.1038/Labinvest.3700665 |
0.316 |
|
| 2007 |
Rimsza LM, LeBlanc ML, Roberts RA, Unger JM, Miller TP, Sabalos CM, Martel RR, Campo E, Rosenwald A, Connors JM, Sehn LH, Johnson N, Gascoyne RD. Major Histocompatibility Class II (MHCII) and Germinal Center Associated Gene Expression Correlate with Overall Survival in Ritiximab and CHOP-Like Treated Diffuse Large B Cell Lymphoma (DLBCL) Patients Using Formalin Fixed Paraffin Embedded (FFPE) Tissues. Blood. 110: 50-50. DOI: 10.1182/Blood.V110.11.50.50 |
0.309 |
|
| 2007 |
Sweetenham JW, Hsi E, Goldman B, LeBlanc M, Tubbs RR, Cook JR, Press OW, Fisher RI, Rimsza LM. Numbers of Lymphoma Associated Macrophages (LAMS) and Regulatory T-Cells (Tregs) in Follicular Lymphoma (FL) Patients (pts) Treated with and without Monoclonal Antibody (MoAb)-Containing Therapy Do Not Correlate with Overall Survival (OS): A Study from the Southwest Oncology Group (SWOG). Blood. 110: 2602-2602. DOI: 10.1182/Blood.V110.11.2602.2602 |
0.356 |
|
| 2006 |
Fan J, Su XG, Levine RA, Nunn ME, Leblanc M. Trees for correlated survival data by goodness of split, with applications to tooth prognosis Journal of the American Statistical Association. 101: 959-967. DOI: 10.1198/016214506000000438 |
0.362 |
|
| 2005 |
Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 8447-52. PMID 16230674 DOI: 10.1200/Jco.2005.03.1674 |
0.356 |
|
| 2005 |
LeBlanc M, Moon J, Crowley J. Adaptive risk group refinement. Biometrics. 61: 370-378. PMID 16011683 DOI: 10.1111/J.1541-0420.2005.020738.X |
0.343 |
|
| 2005 |
Urba SG, Moon J, Giri PGS, Adelstein DJ, Hanna EY, Yoo GH, LeBlanc M, Ensley JF, Schuller DE. Organ Preservation for Advanced Resectable Cancer of the Base of Tongue and Hypopharynx: A Southwest Oncology Group Trial Journal of Clinical Oncology. 23: 88-95. PMID 15625363 DOI: 10.1200/Jco.2005.04.017 |
0.368 |
|
| 2005 |
Press OW, Unger J, Maloney D, Braziel RM, LeBlanc M, Grogan T, Miller TP, Fisher RI. An Update of a Phase II Trial of CHOP Followed by Tositumomab/Iodine I-131 Tositumomab (Bexxar®) for Front-Line Treatment of Advanced Stage, Follicular Lymphoma: Southwest Oncology Group Protocol 9911. Blood. 106: 352-352. DOI: 10.1182/Blood.V106.11.352.352 |
0.388 |
|
| 2004 |
Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. The New England Journal of Medicine. 351: 2159-69. PMID 15548776 DOI: 10.1056/Nejmoa041869 |
0.33 |
|
| 2004 |
Dave SS, Wright G, Tan B, Rosenwald A, Chan WC, Greiner TC, Weisenburger DD, Lynch JC, Vose JM, Armitage JO, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, ... LeBlanc M, et al. Lymphdx: A Custom Microarray for Molecular Diagnosis and Prognosis in Non-Hodgkin Lymphoma. Blood. 104: 701-701. DOI: 10.1182/Blood.V104.11.701.701 |
0.337 |
|
| 2004 |
Crowley JJ, McCoy J, LeBlanc M, Barlogie B. Extreme Regression: A Statistical Technique for Finding Good or Poor Prognostic Groups, Illustrated Using Myeloma Patient Data from Intergroup Trial S9321. Blood. 104: 5202-5202. DOI: 10.1182/Blood.V104.11.5202.5202 |
0.416 |
|
| 2004 |
Spier CM, LeBlanc M, Chase EM, Fisher RI, Miller TP. Histologic Subtypes Do Not Confer Unique Outcomes in Early-Stage Lymphoma: Long-Term Follow-Up of SWOG 8736. Blood. 104: 3263-3263. DOI: 10.1182/Blood.V104.11.3263.3263 |
0.398 |
|
| 2004 |
Miller TP, Unger JM, Spier C, Stea B, Cantu E, LeBlanc M, Fisher RI. Effect of Adding Rituximab to Three Cycles of CHOP Plus Invoved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG-0014). Blood. 104: 158-158. DOI: 10.1182/Blood.V104.11.158.158 |
0.413 |
|
| 2003 |
Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, ... ... LeBlanc M, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. The Journal of Experimental Medicine. 198: 851-62. PMID 12975453 DOI: 10.1084/Jem.20031074 |
0.343 |
|
| 2003 |
Blayney DW, LeBlanc ML, Grogan T, Gaynor ER, Chapman RA, Spiridonidis CH, Taylor SA, Bearman SI, Miller TP, Fisher RI. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 2466-73. PMID 12829664 DOI: 10.1200/Jco.2003.06.137 |
0.389 |
|
| 2003 |
Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood. 102: 1606-12. PMID 12738671 DOI: 10.1182/Blood-2003-01-0287 |
0.305 |
|
| 2003 |
Pauler DK, Hardin J, Faulkner JR, LeBlanc M, Crowley JJ. Survival Analysis with Gene Expression Arrays Handbook of Statistics. 23: 675-688. DOI: 10.1016/S0169-7161(03)23037-6 |
0.33 |
|
| 2002 |
LeBlanc M, Jacobson J, Crowley J. Partitioning and peeling for constructing prognostic groups. Statistical Methods in Medical Research. 11: 247-274. PMID 12094758 DOI: 10.1191/0962280202Sm286Ra |
0.334 |
|
| 1999 |
LeBlanc M, Crowley J. Adaptive regression splines in the Cox model. Biometrics. 55: 204-213. PMID 11318156 DOI: 10.1111/J.0006-341X.1999.00204.X |
0.34 |
|
| 1999 |
LeBlanc M, Crowley J. Using the bootstrap for estimation in group sequential designs: an application to a clinical trial for nasopharyngeal cancer. Statistics in Medicine. 18: 2635-2644. PMID 10495461 DOI: 10.1002/(Sici)1097-0258(19991015)18:19<2635::Aid-Sim200>3.0.Co;2-7 |
0.356 |
|
| 1999 |
Liu PY, Leblanc M, Desai M. False positive rates of randomized phase II designs Controlled Clinical Trials. 20: 343-352. PMID 10440561 DOI: 10.1016/S0197-2456(99)00009-4 |
0.335 |
|
| 1998 |
Wirth A, Prince HM, Wolf M, Machida U, Kami M, Hirai H, Mounier N, Gisselbrecht C, Lepage E, Kosmas C, Malamos NA, Antonopoulos MJ, Decaudin D, Miller TP, LeBlanc M, et al. Treatment of intermediate-grade and high-grade non-Hodgkin's lymphoma [1] (multiple letters) The New England Journal of Medicine. 339: 1475-1477. PMID 9841317 DOI: 10.1056/Nejm199811123392012 |
0.305 |
|
| 1998 |
Al-Sarraf M, LeBlanc M, Giri PGS, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099 Journal of Clinical Oncology. 16: 1310-1317. PMID 9552031 DOI: 10.1200/Jco.1998.16.4.1310 |
0.399 |
|
| 1998 |
Press OW, LeBlanc M, O'Rourke TJ, Gagnet S, Chapman RA, Balcerzak SP, Fisher RI. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 574-8. PMID 9469343 DOI: 10.1200/Jco.1998.16.2.574 |
0.399 |
|
| 1998 |
Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, Blume KG, LeBlanc M, Fisher RI. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial. Journal of Clinical Oncology. 16: 48-55. PMID 9440722 DOI: 10.1200/Jco.1998.16.1.48 |
0.362 |
|
| 1997 |
Miller TP, LeBlanc M, Grogan TM, Fisher RI, Graff JC. Follicular lymphomas: Do histologic subtypes predict outcome? Hematology/Oncology Clinics of North America. 11: 893-900. PMID 9336720 DOI: 10.1016/S0889-8588(05)70468-8 |
0.364 |
|
| 1996 |
Giri PG, LeBlanc M, Al-Sarraf M, Fu KK, Cooper J, Vuong T, Forastiere A, Adams G, Sakr W, Schuller D, Ensley J. 8 Improved survival with chemotherapy and radiation therapy versus radiation therapy alone in advanced nasopharyngeal cancer. Preliminary results of an intergroup randomized trial. Int 0099, SWOG 8892, RTOG 8817, ECOG 2388 International Journal of Radiation Oncology Biology Physics. 36: 162. DOI: 10.1016/S0360-3016(97)85348-5 |
0.316 |
|
| 1995 |
Leblanc M, Crowley J. Semiparametric Regression Functionals Journal of the American Statistical Association. 90: 95-105. DOI: 10.1080/01621459.1995.10476492 |
0.313 |
|
| 1993 |
Leblanc M, Crowley J. Survival Trees by Goodness of Split Journal of the American Statistical Association. 88: 457-467. DOI: 10.1080/01621459.1993.10476296 |
0.32 |
|
| 1990 |
Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 8: 1563-74. PMID 2167954 DOI: 10.1200/Jco.1990.8.9.1563 |
0.407 |
|
| Show low-probability matches. |